Compare Home Depot Inc (HD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Pfizer Inc — how do they compare? Home Depot Inc trades at $296.38 (market cap $294.79B), while Pfizer Inc trades at $27.83 (market cap $158.56B). The key difference: Home Depot Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Pfizer Inc for 158 Days on average.
| HD | PFE | |
|---|---|---|
Market Cap | $294.79B | $158.56B |
Volume | 8,693,917 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $29.02 |
52-Week Low | $281.15 | $23.67 |
Typical Hold Time | 139 Days | 158 Days |
Enterprise Value | $355.27B | $210.06B |
Dividend Yield | 3.15% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $285.77, down 0.32% with bearish technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 104.3%, net margin 8.41%). Revenue grew to $159.51B in 2025, though margins face pressure from housing market headwinds. Analysts maintain a bullish consensus with a $379.93 price target (58.7% buy ratings). Recent institutional activity shows mixed positioning amid weak big-ticket demand.
HD offers long-term value with analyst upside of 33% but faces near-term risks from rising mortgage rates and margin compression. The Pro business and digital initiatives provide growth levers, while technical weakness suggests cautious entry points. Investors should weigh strong cash flow generation against cyclical housing exposure.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
